Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in mid-November.

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and…

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square meters. The extension with state-of-the-art office…

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the Therapeutic Area Ophthalmology (AMD – age-related macular…

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.